HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools
00
Days
00
Hours
00
Mins
00
Sec
Register Now!
Market News Stocks News ETF News Crypto News

Capricor Therapeutics

Contributing Author

Recent Articles by Capricor Therapeutics

Dec-04
Capricor Therapeutics Announces Proposed Public Offering of Common Stock CAPR -15.22% GlobeNewswire
Dec-03
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy CAPR GlobeNewswire
Nov-24
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025 CAPR GlobeNewswire
Nov-10
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update CAPR GlobeNewswire
Nov-03
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel CAPR GlobeNewswire
Oct-31
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 CAPR GlobeNewswire
Sep-25
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting CAPR GlobeNewswire
Sep-09
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel CAPR GlobeNewswire
Aug-18
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine CAPR GlobeNewswire
Aug-11
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update CAPR GlobeNewswire
Aug-08
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA CAPR GlobeNewswire
Aug-06
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 CAPR GlobeNewswire
Jul-28
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jul-11
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-24
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-20
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-17
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program CAPR GlobeNewswire
Jun-11
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program CAPR GlobeNewswire
May-13
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update CAPR GlobeNewswire
May-13
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer CAPR GlobeNewswire
May-06
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 CAPR GlobeNewswire
May-05
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy CAPR GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.